RecruitingPhase 2Phase 3NCT06223828
Azithromycin for Critical Asthma - Pediatrics
Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking
Sponsor
Johns Hopkins All Children's Hospital
Enrollment
100 participants
Start Date
Apr 2, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Eligibility
Min Age: 3 YearsMax Age: 17 Years
Inclusion Criteria5
- Age 3-17 years
- Admission to the PICU
- Primary diagnosis of critical asthma
- Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
- Prescription for intravenous systemic corticosteroids
Exclusion Criteria5
- Critical Congenital Heart Disease Unrepaired
- Tracheostomy Dependence at Admission
- Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
- Past Medical History of Prolonged QT Syndrome or Arrhythmias
- Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Interventions
DRUGAzithromycin
10mg/kg/dose (max dose 500mg) once daily for 3 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06223828
Related Trials
Behavioral Health Collaborative Care Model in an ICU Recovery Clinic
NCT073725861 location
IL-6 and Hemogram-Derived Inflammatory Indices for Mortality Prediction in Postoperative ICU Patients
NCT074601411 location
Effects of Negative Pressure Ventilation Onto Hemodynamics and Right Ventricular Funktion in Patients After Implantation of a Left Ventricular Assist Device.
NCT070345991 location
Modern Technologies in Lower Respiratory Tract Infections in Children
NCT073817902 locations
Music Listening: A Mechanistic Trial
NCT055410291 location